Barrow, Hanley, Mewhinney & Strauss
LXRX icon

Barrow, Hanley, Mewhinney & Strauss’s Lexicon Pharmaceuticals LXRX Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-114,679
Closed -$224K – 366
2020
Q1 		$224K Sell
114,679
-65,515
-36% -$195K ﹤0.01% 268
2019
Q4 		$748K Buy
+180,194
New +$694K ﹤0.01% 250

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's LXRX Position: Q2 2020 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2020, closing a stake of 114,679 shares — an estimated $224K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in LXRX in Q4 2019 and held it in 2 quarters. The position peaked at $748K in Q4 2019. 108 funds tracked by Wall St. Rank hold LXRX as of Q2 2020.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Lexicon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 114,679 Lexicon Pharmaceuticals shares in Q2 2020, an estimated $224K.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Lexicon Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Lexicon Pharmaceuticals position peaked at $748K in Q4 2019.
  • 108 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2020.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2020, filed 12 Aug 2020.